Investor''s Presentation

Investor''s Presentation Presented During Annual General Meeting dt 22-09-2022

7 days ago



Sentiments detected

Positive 25
  • With the introduction of our subsidiary, 3B BlackBio Biotech India Limited in 2011 which is also now over a decade old and is now regarded as one of the most reliable molecular diagnostic company in the healthcare market.

  • We have stood strong in the tests of time and delivered the best solutions possible to our customers over five memorable decades.

  • We appreciate and thank you for the continuous trust you have put in our company.

  • Throughout its 50-year history KILPEST has risen to the occasion again and again with hard work, dedication and cooperation with partners near and far.

  • We look forward to the next 50 Years with greater satisfaction to all our stakeholders.

  • Our growth rate has been consistent since pre-covid period and we have been achieving a growth rate of 30-35% year on year.

  • In FY2021-22, the Non-COVID Revenue is INR 265.30 Million which shows that we are going strong on our growth trajectory of over 30% for Non-COVID products (YoY).

  • With our clearly defined strategic priorities, we will hopefully continue to have a growth rate of 30-35% for the year 2022-23 as well.

  • With COVID, the number of labs have increased and we are trying to increase our footprints for NON-COVID products in these labs.

  • We are expanding our footprints in the international market where we are now present in more than 29 countries which including USA, UK, & countries spanning Europe, Africa, Middle East & APAC.

  • Our growth in the international market is evident from the export sales that has been generated in these past years.

  • We are proud to state the fact that your subsidiary company 3B BlackBio has launched its own subsidiary company in the United Kingdom after entering into a Joint Venture Agreement with its European Distributor, HS Biolabs Limited based in Manchester, UK.

  • The technical team has already been appointed and we are currently working to increase the Sales & Marketing Team also apart from the present team.

  • Europe Limited has started participating in International Conferences from which we expect to get more traction.

  • With these conferences, the visibility of TRUPCR Europe has increased and we are getting enquiries for providing distributorships and OEM solutions through which we will expand our footprints across Europe.

  • With enhanced visibility and full marketing team in place, the real benefits of the subsidiary will start coming in the next financial year.

  • Rapid Kit Business & Next-Gen Sequencing (NGS) Verticals Our Rapid Kit manufacturing plant is ready & we are optimizing the products in R&D which have market potential, other than COVID Testing Kits.

  • We will be launching some novel products in FY 2022-23 which are currently under R&D Stage which will allow us to capture a bigger market segment with better price realization.

  • M&A valuations globally have gone high due to demand from molecular diagnostic companies which are flushed with cash.

  • We are hopeful that scheme of amalgamation would come in force in the near future.

  • I would like to take cognizance of the fact that your company was conferred with the “Outstanding Achievement Award” for the 2nd time by the FMPCCI, Madhya Pradesh for excellence in R&D and Innovative Products category for the year 2021-22.

  • Best Under a Billion” in FY 2021-22 for its long-term sustainable performance.

  • I wish to end with a note of gratitude to all our valued customers, both domestic & international, for their continued support.

  • We also wish to express our gratitude to the Government of India, Ministry of Health, Government of Madhya Pradesh for their sustained support to the company and its initiatives.

  • It is their support that helps us to continue building a self-sufficient company and accomplishing the goal of our Hon’ble Prime Minister of becoming ‘AatmaNirbhar Bharat’.

Negative 0

    Mentioned Phrases & Organizations

    Important keywords detected (20+)

    covid (8)
    subsidiary (7)
    market (7)
    products (7)
    growth (6)
    business (5)
    india (5)
    diagnostic (5)
    international (5)
    europe (5)
    shareholders (4)
    like (4)
    kilpest (4)
    molecular (4)
    stakeholders (4)
    put (4)
    team (4)
    molecular diagnostic (4)
    financial (3)
    started (3)

    Organizations identified (10+)

    Kilpest (2)
    TRUPCR (2)
    KILPEST (1)
    BlackBio (1)
    European Distributor (1)
    HS Biolabs Limited (1)
    Europe Limited (1)
    International Conferences (1)
    Indore Bench (1)
    Kilpest India Limited (1)

    Features are experimental.